Pivotal phase 3 study of Zanubrutinib vs. Bendamustine

 IMAGE   06/2020

Pivotal phase 3 study of Zanubrutinib + Rituximab vs. Bendamustine + Rituximab in previously untreated MCL patients ineligible for SCT

{{Rate this publication}}

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service